Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which ...

The decision reaffirming the FDA's oversight authority over cell and gene therapy products was praised by the International ...

The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research ...

Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.

Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

Four US cancer centers are partnering with leading technology firms to analyze cancer patient data while maintaining privacy and regulatory compliance.

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who used a chatbot or met with a genetic counselor.

Foresight said that Roche's asserted trade secrets were not secret and that the technologies at the heart of the claim are fundamentally different. The decision reaffirming the FDA's oversight ...